Phase 3 N=1,950 Stent vs. Indomethacin for Preventing Post-ERCP Pancreatitis
Post-ERCP Pancreatitis
Primary: The Proportion of Subjects in Each Study Group With Post-ERCP Pancreatitis — 145; 110; 137; 90 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=241 SCS as an Option for Chronic Low Back and/or Leg Pain Instead of Surgery
Chronic Pain
Primary: Responder Rate — 51; 5 Participants
Phase 2 N=35 TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas
Lymphomas · Solid Tumors · NSCLC
Primary: Phase 2: Response Rate of This Combination in Participants With Colon Cancer, Non-small Cell Lung Cancer (NSCLC), and Granulosa Cell Ovarian Cancer — 0; 0; 0; 1…
Phase 2 N=24 Bisphosphonates for Prevention of Post-Denosumab Bone Loss
IOP · Osteoporosis
Primary: Difference in BMD at the Lumbar Spine (L1-4) Within Group — -1.1; -2.4 percentage of change
N/A N=86 Examining Community-based Effectiveness of a Substance Use and HIV Risk Reduction Intervention for Young Men of Color
Substance Use · Sexual Risk
Primary: Illicit Drug Use Days — 3.04; 11.62; 2.00; 6.04 days — p=.19
Phase 3 N=120 A Study Evaluating the Long-term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis (CF) Particpants 6 Years and Older and F/MF Genotypes
Cystic Fibrosis
Primary: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 118; 13 Participants
Phase 2 N=17 Compassionate Use Study of Tenalisib (RP6530)
Hematological Malignancies
Primary: Treatment-related Adverse Events — 4 Participants
Early Phase 1 N=31 Acute Effects of E-Cigarette Aerosol Inhalation
Endothelial Dysfunction · Biochemical Markers
Primary: Inflammatory Blood-Based Biomarkers — 5 fold change — p=0.05
Phase 2 N=11 Everolimus for Children With Recurrent or Progressive Ependymoma
Recurrent Childhood Ependymoma
Primary: Objective Response Rate (Complete Response Rate and Partial Response Rate) Following Treatment With Everolimus for Children With Recurrent or Progressive Ependymomas…
N/A N=160 Treatment With Intent to Generate Endovascular Reperfusion
Ischemic Stroke
Primary: Successful Reperfusion, Defined as mTICI Score ≥ 2b — 130 Participants
N/A N=14 Home Visitation Enhancing Linkages Project
Substance Use
Primary: Feasibility: e-SBI Session 1 Completion Rate — 8; 4; 2; 0 Participants
Phase 3 N=1,325 Meningococcal Serogroup ACYWX Conjugate Vaccine in Comparison With MenACWY-TT Conjugate Vaccine
Meningitis
Primary: Number of Participants With Seroprotection for Meningitis Serogroups A, C, W and Y — 373; 191; 366; 180 Participants
N/A N=10 Pediatric Teleneuromodulation
Cerebral Palsy (CP)
Primary: Status/Safety Assessment — 4; 7; 20; 12 number of sessions symptom reported
Phase 4 N=108 SSRI Effects on Depression and Immunity in HIV/AIDS
Depression · HIV · AIDS
Primary: Natural Killer Cell Activity, Measured in Lytic Units [Bryant J, Day R, Whiteside TL, and Herbeman RB: Calculation of Lytic Units for the Expression of Cell-mediated…
Phase 2 N=18 VE303 for Treatment of Hepatic Encephalopathy (HE)
Cirrhosis · Hepatic Encephalopathy
Primary: Number of Participants Who Experienced Serious Adverse Events up to Week 6 — 2; 0 Participants